PolyPid (NASDAQ:PYPD) Upgraded at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of PolyPid (NASDAQ:PYPD) to a strong-buy rating in a report published on Tuesday morning,Zacks.com reports.

Several other brokerages also recently commented on PYPD. HC Wainwright lowered their target price on shares of PolyPid from $14.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, December 26th. Rodman & Renshaw began coverage on shares of PolyPid in a report on Tuesday. They set a “buy” rating and a $13.00 target price on the stock. Finally, Craig Hallum started coverage on shares of PolyPid in a research report on Monday, November 4th. They set a “buy” rating and a $10.00 price target on the stock.

PolyPid Price Performance

Shares of PYPD opened at $2.99 on Tuesday. PolyPid has a 12-month low of $2.37 and a 12-month high of $7.00. The stock has a market cap of $14.34 million, a P/E ratio of -0.38 and a beta of 1.32. The business’s fifty day moving average is $3.10 and its 200 day moving average is $3.36. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in PolyPid stock. Stonepine Capital Management LLC bought a new position in PolyPid Ltd. (NASDAQ:PYPD) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned about 2.89% of PolyPid at the end of the most recent quarter. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.